Hi 

MindBio Therapeutics has been featured prominently in one of Australia's leading newspapers, The Australian Financial Review.

MindBio will soon commence the first of two clinical trials, including the world’s first Phase 2 take-home LSD-Microdosing clinical trial in patients with Major Depressive Disorder.  

It's our sincere belief that this could transform the way depression is treated and provide new hope for those grappling with this debilitating condition.

We encourage you to read the full article in The Australian Financial Review, which can be accessed here:

The Acid Test: Why LSD is Making a Comeback

Two fully funded Phase 2 take-home LSD-Microdosing clinical trials.

MindBio has two fully funded Phase 2 LSD-Microdosing clinical trials. The first trial focuses on Major Depressive Disorder, where 20 patients meeting DSM-V criteria will receive an open-label 8-week LSD microdosing treatment regimen in a naturalistic at-home setting. This trial will serve as the basis for continuing a much larger Phase 2b triple-dummy, active placebo-controlled trial in depressed patients.

The second trial explores the effectiveness of LSD-Microdosing in conjunction with Meaning Centred Psychotherapy in late-stage cancer patients experiencing emotional distress. This randomized, double-blind, and placebo-controlled trial will involve 40 participants and is set to begin recruiting participants for the trial shortly.

Australia heads towards medical legalisation of psychedelics on 1 July 2023.

MindBio's ability to demonstrate the safety and efficacy of microdosing interventions in real-world settings is revolutionary for the industry. Regulators are seeking credible data to make special access approvals for psychedelic medicines, which have shown profound healing effects on patients with mental health conditions.

Australia has recently advanced its regulatory framework by medically legalizing psilocybin and MDMA effective 1 July 2023. Conceivably, the surprising change in regulatory sentiment and allowing pre-Phase 3 use of a drug in Australia is due to the ineffectiveness of existing treatments to abate the escalating mental health crisis in Australia.

Thank you for your support of MindBio Therapeutics. Together, we hope to redefine the landscape of mental health treatment and bring lasting, effective solutions to those in need.

Should you have any questions or comments, please don't hesitate to reach out. We always appreciate your feedback and insights.

Yours in health,

Justin Hanka 

Cofounder and Chief Executive

Receive our latest updates here:

https://www.mindbiotherapeutics.com/get-updates

Follow MindBio on LinkedIn:

https://www.linkedin.com/company/mindbio-therapeutics/?viewAsMember=true

Follow CEO Justin Hanka on LinkedIn: 

https://www.linkedin.com/in/justinhanka/